Grigory A. Efimov

1.4k total citations
46 papers, 555 citations indexed

About

Grigory A. Efimov is a scholar working on Immunology, Oncology and Infectious Diseases. According to data from OpenAlex, Grigory A. Efimov has authored 46 papers receiving a total of 555 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Immunology, 18 papers in Oncology and 13 papers in Infectious Diseases. Recurrent topics in Grigory A. Efimov's work include SARS-CoV-2 and COVID-19 Research (13 papers), Immunotherapy and Immune Responses (13 papers) and T-cell and B-cell Immunology (11 papers). Grigory A. Efimov is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (13 papers), Immunotherapy and Immune Responses (13 papers) and T-cell and B-cell Immunology (11 papers). Grigory A. Efimov collaborates with scholars based in Russia, Germany and United States. Grigory A. Efimov's co-authors include Sergei A. Nedospasov, Marina S. Drutskaya, Andrey Kruglov, С. В. Тиллиб, Dmitry V. Kuprash, Vladislav V. Mokhonov, Dmitry B. Malko, С А Недоспасов, Dmitriy M. Chudakov and Anna Kuchmiy and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Nature Communications.

In The Last Decade

Grigory A. Efimov

40 papers receiving 525 citations

Peers

Countries citing papers authored by Grigory A. Efimov

Since Specialization

Citations

This map shows the geographic impact of Grigory A. Efimov's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Grigory A. Efimov with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Grigory A. Efimov more than expected).

Fields of papers citing papers by Grigory A. Efimov

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Grigory A. Efimov. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Grigory A. Efimov. The network helps show where Grigory A. Efimov may publish in the future.

Co-authorship network of co-authors of Grigory A. Efimov

This figure shows the co-authorship network connecting the top 25 collaborators of Grigory A. Efimov. A scholar is included among the top collaborators of Grigory A. Efimov based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Grigory A. Efimov. Grigory A. Efimov is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Immunogenicity and safety of a recombinant adenovirus type-5 COVID-19 vaccine in adults: Data from a randomised, double-blind, placebo-controlled, single-dose, phase 3 trial in Russia 2023 ·PLoS ONE ·Dmitry Lioznov, (unknown), (unknown), Ksenia V. Zornikova, Yana Serdyuk, Grigory A. Efimov, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Tao Zhu, (unknown), (unknown)	6
2	Transgenic HA-1-Specific CD8+ T-Lymphocytes Selectively Target Leukemic Cells 2023 ·Cancers ·(unknown), (unknown), (unknown), (unknown), Anna N. Gabashvili, (unknown), (unknown), Ksenia V. Zornikova, (unknown), Murad Vagida, (unknown), Grigory A. Efimov	4
3	Structural assessment of HLA-A2-restricted SARS-CoV-2 spike epitopes recognized by public and private T-cell receptors 2022 ·Nature Communications ·Daichao Wu, A. V. Kolesnikov, Rui Yin, Johnathan D. Guest, Ragul Gowthaman, (unknown), Yana Serdyuk, (unknown), Grigory A. Efimov, Brian G. Pierce, Roy A. Mariuzza	27
4	Memory B Cells Induced by Sputnik V Vaccination Produce SARS-CoV-2 Neutralizing Antibodies Upon Ex Vivo Restimulation 2022 ·Frontiers in Immunology ·(unknown), Sergey V. Kulemzin, (unknown), (unknown), Grigory A. Efimov, (unknown), (unknown), Andrey A. Gorchakov, Alexander V. Taranin, Alexander Filatov	11
5	Clonal diversity predicts persistence of SARS-CoV-2 epitope-specific T-cell response 2022 ·Communications Biology ·Ksenia V. Zornikova, (unknown), (unknown), (unknown), (unknown), Aleksei Titov, Ivan V. Zvyagin, Grigory A. Efimov	9
6	Longitudinal high-throughput TCR repertoire profiling reveals the dynamics of T-cell memory formation after mild COVID-19 infection 2021 ·eLife ·Anastasia A. Minervina, Ekaterina A. Komech, Aleksei Titov, (unknown), Elisa Rosati, Ilgar Z. Mamedov, André Franke, Grigory A. Efimov, Dmitriy M. Chudakov, Thierry Mora, Aleksandra M. Walczak, Yuri B. Lebedev, Mikhail V. Pogorelyy	72
7	Antibodies to the N-Terminal Domain of Angiotensin-Converting Enzyme (ACE2) That Block Its Interaction with SARS-CoV-2 S Protein 2021 ·Doklady Biochemistry and Biophysics ·(unknown), (unknown), Sergei Chuvpilo, Grigory A. Efimov, (unknown), Marina S. Drutskaya, Sergei A. Nedospasov	5
8	Prospects for Using the ELISPOT Technological Platform as Part of Anti-Epidemic Measures Against the New Coronavirus Infection COVID-19 2020 ·SHILAP Revista de lepidopterología ·Dmitry Poteryaev, (unknown), Grigory A. Efimov, (unknown)	3
9	Модификация цитотоксических лимфоцитов рецептором, специфичным к минорному антигену гистосовместимости ACC1-Y 2019 ·Молекулярная биология ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Grigory A. Efimov	3
10	Effect of <i>CTLA4</i> gene polymorphism on relapse probability among patients with acute leukemias after allogenic hematopoietic stem cells transplantation 2019 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), (unknown), (unknown), (unknown), Larisa A. Kuzmina, Grigory A. Efimov, Е. Н. Паровичникова, Savchenko Vg	1
11	VHH-Based Bispecific Antibodies Targeting Cytokine Production 2017 ·Frontiers in Immunology ·(unknown), Kamar‐Sulu N. Atretkhany, Vladislav V. Mokhonov, Grigory A. Efimov, Andrey Kruglov, С. В. Тиллиб, Marina S. Drutskaya, Sergei A. Nedospasov	31
12	IMMUNOBIOLOGY OF ACUTE GRAFT-VERSUS-HOST DISEASE 2016 ·Medical Immunology (Russia) ·Grigory A. Efimov, Alexander Vdovin, (unknown), Sergey Filkin, (unknown), Savchenko Vg	6
13	Comparative analysis of minor histocompatibility antigens genotyping methods 2016 ·Oncohematology ·Alexander Vdovin, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Grigory A. Efimov	1
14	CANCER IMMUNOTHERAPY BASED ON THE BLOCKADE OF IMMUNE CHECKPOINTS 2015 ·SHILAP Revista de lepidopterología ·(unknown), Grigory A. Efimov, Marina S. Drutskaya, С А Недоспасов	7
15	Интерлейкин-6 – от молекулярных механизмов передачи сигнала к физиологическим функциям и терапевтическим мишеням 2015 ·Молекулярная биология ·(unknown), (unknown), (unknown), Grigory A. Efimov, Sergei A. Nedospasov	14
16	Experimental models of arthritis in which pathogenesis is dependent on TNF expression 2014 ·Biochemistry (Moscow) ·Marina S. Drutskaya, Grigory A. Efimov, (unknown), (unknown), Dmitriy M. Chudakov, С. В. Тиллиб, Andrey Kruglov, Sergei A. Nedospasov	13
17	Modern anti-cytokine therapy of autoimmune diseases 2014 ·Biochemistry (Moscow) ·(unknown), Grigory A. Efimov, Marina S. Drutskaya, Andrey Kruglov, Sergei A. Nedospasov	18
18	New trends in anti-cytokine therapy 2014 ·Grigory A. Efimov, Andrey Kruglov, (unknown), (unknown), Sergei A. Nedospasov	1
19	Single-domain antibody-based ligands for immunoaffinity separation of recombinant human lactoferrin from the goat lactoferrin of transgenic goat milk 2014 ·Journal of Chromatography B ·С. В. Тиллиб, (unknown), Т. И. Иванова, (unknown), Grigory A. Efimov, (unknown), (unknown), I. L. Gol’dman, (unknown)	19
20	Modalities of Experimental TNF Blockade In Vivo: Mouse Models 2010 ·Advances in experimental medicine and biology ·Andrey Kruglov, Alexei V. Tumanov, Sergei I. Grivennikov, (unknown), Anna Kuchmiy, Grigory A. Efimov, Marina S. Drutskaya, Jürgen Scheller, Dmitry V. Kuprash, Sergei A. Nedospasov	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact